Physician profile
Paul E Bejarano
NPI 1679551485
$15,329.93
in general payments reported to CMS, 2019-2025
38 companies · $1,960 in 2025
The $1,960 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,233 · 2020: $1,049 · 2021: $1,542 · 2022: $2,026 · 2023: $2,118 · 2024: $2,402 · 2025: $1,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,480.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,158.17 | 2019-2025 | |
| Biotronik INC. | $1,823.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $1,463.84 | 2019-2024 | Xarelto |
| Amgen INC. | $1,150.14 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $1,149.67 | 2019-2025 | |
| Abbott Laboratories | $1,142.80 | 2019-2025 | Gallant, Assurity, Jot Dx |
| E.R. Squibb & Sons, L.L.C. | $863.58 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $752.30 | 2021-2025 | Verquvo, Capvaxive |
| Abiomed | $619.95 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $507.28 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.78 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $484.11 | 2019-2025 | General - Ep |
| Edwards Lifesciences Corporation | $430.16 | 2023-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astellas Pharma US INC | $416.39 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $222.24 | 2022-2024 | Opsumit, Uptravi |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bejarano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.